We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




MALDI-TOF Mass Spectrometry Differentiates Streptococcus Species

By LabMedica International staff writers
Posted on 02 May 2016
Print article
Image: The Vitek MS laser desorption ionization time-of-flight mass spectrometry for identification of bacteria platform (Photo courtesy of bioMérieux).
Image: The Vitek MS laser desorption ionization time-of-flight mass spectrometry for identification of bacteria platform (Photo courtesy of bioMérieux).
It is clinically relevant to distinguish Streptococcus pneumoniae from other less virulent, members of the viridans group streptococci (VGS) and accurate species determination within the VGS and more specifically within the mitis subgroup is traditionally difficult.

Matrix-assisted laser desorption ionization–time-of-flight (MALDI-TOF) mass spectrometry shows promising results for differentiation of species within the mitis group but further exploration and validation are needed. To complicate the diagnostic challenges within the VGS, in 2004, a new species within the VGS that closely resembles S. pneumoniae was described and designated as S. pseudopneumoniae.

Medical microbiologists at the VU University Medical Center (Amsterdam, The Netherlands) evaluated the ability of two MALDI-TOF mass spectrometry platforms for species differentiation within the mitis subgroup. A panel consisting of 29 clinical and eight reference isolates was tested. The reference strains used included two S. pneumoniae, two S. pseudopneumoniae, two S. mitis and two S. oralis. As a gold standard, they combined real-time polymerase chain reaction (PCR) assays targeting the Autolysin-Encoding Gene (lytA), the recombinase A (recA), and Spn9802, which were adapted from previously described methods.

MALDI-TOF mass spectrometry was performed with either the Microflex platform (Bruker Daltonics; Bremen, Germany) or the Vitek MS platform (bioMérieux; Marcy l’Etiole, France). The PCR assays targeting the lytA and recA genes are specific for S. pneumoniae and S. pseudopneumoniae, respectively. The PCR assay targeting the Spn9802 fragment detects both S. pneumoniae and S. pseudopneumoniae but no other VGS. Hence, strains that tested negative in all three PCR assays were designated S. mitis/oralis.

The Vitek MS correctly identified 10/11 Streptococcus pneumoniae, 13/13 Streptococcus pseudopneumoniae, and 12/13 S. mitis/oralis. The Microflex correctly identified 9/11 S. pneumoniae, 0/13 S. pseudopneumoniae, and 13/13 S. mitis/oralis. MALDI-TOF is a powerful tool for species determination within the mitis group and diagnostic accuracy varies depending on platform and database used. The study was published in the May 2016 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
VU University Medical Center
Bruker Daltonics
bioMérieux
Gold Member
Troponin T QC
Troponin T Quality Control
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Automated Immunoassay Analyzer
Phadia 1000
New
Celiac Disease Test
AESKULISA tTg-A New Generation

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.